采用柱盒-放射免疫分析法联合技术对细胞内齐多夫定磷酸盐进行定量分析。
Quantitation of intracellular zidovudine phosphates by use of combined cartridge-radioimmunoassay methodology.
作者信息
Robbins B L, Waibel B H, Fridland A
机构信息
Department of Infectious Disease, St. Jude Children's Research Hospital, Memphis, Tennessee 38105, USA.
出版信息
Antimicrob Agents Chemother. 1996 Nov;40(11):2651-4. doi: 10.1128/AAC.40.11.2651.
Abstract
This report describes the development of a potentially clinical method to measure the cellular metabolites of zidovudine (ZDV) in patients receiving the drug. This new method combines the use of Sep-Pak cartridges to separate ZDV phosphates with radioimmunoassaying to quantitate ZDV. The detection limit is 0.02 pmol/10(6) cells, and this assay can measure a wide range of intracellular drug concentrations. The use of the cartridge-radioimmunoassay methodology should prove very useful for in vivo cellular pharmacokinetic studies of ZDV.
摘要
本报告描述了一种潜在的临床方法的开发，该方法用于测量接受齐多夫定（ZDV）治疗的患者体内齐多夫定的细胞代谢产物。这种新方法结合了使用Sep-Pak柱来分离齐多夫定磷酸盐，并采用放射免疫测定法定量齐多夫定。检测限为0.02 pmol/10⁶个细胞，该测定法可测量广泛的细胞内药物浓度范围。柱-放射免疫测定法的应用对于齐多夫定的体内细胞药代动力学研究应会非常有用。
相似文献
1
Quantitation of intracellular zidovudine phosphates by use of combined cartridge-radioimmunoassay methodology.
Antimicrob Agents Chemother. 1996 Nov;40(11):2651-4. doi: 10.1128/AAC.40.11.2651.
2
Quantification of zidovudine and individual zidovudine phosphates in peripheral blood mononuclear cells by a combined isocratic high performance liquid chromatography radioimmunoassay method.
J Pharm Biomed Anal. 1996 Feb;14(4):491-9. doi: 10.1016/0731-7085(95)01649-x.
3
Enzymatic assay for measurement of zidovudine triphosphate in peripheral blood mononuclear cells.
Antimicrob Agents Chemother. 1994 Jan;38(1):115-21. doi: 10.1128/AAC.38.1.115.
4
The effect of zidovudine dose on the formation of intracellular phosphorylated metabolites.
AIDS. 1996 Oct;10(12):1361-7. doi: 10.1097/00002030-199610000-00008.
5
Intracellular zidovudine (ZDV) and ZDV phosphates as measured by a validated combined high-pressure liquid chromatography-radioimmunoassay procedure.
Antimicrob Agents Chemother. 1992 Nov;36(11):2473-7. doi: 10.1128/AAC.36.11.2473.
6
Determination of zidovudine triphosphate intracellular concentrations in peripheral blood mononuclear cells from human immunodeficiency virus-infected individuals by tandem mass spectrometry.
Antimicrob Agents Chemother. 1999 Dec;43(12):2964-8. doi: 10.1128/AAC.43.12.2964.
7
In vitro measurement of phosphorylated zidovudine in peripheral blood leucocytes.
Ther Drug Monit. 1990 Sep;12(5):481-9. doi: 10.1097/00007691-199009000-00013.
8
Metabolism of Zidovudine.
Gen Pharmacol. 1995 Nov;26(7):1469-75. doi: 10.1016/0306-3623(95)00047-x.
9
Phosphorylated zidovudine concentrations in mononuclear cells in pediatric patients with human immunodeficiency virus infections.
Pediatr AIDS HIV Infect. 1997 Apr;8(2):120-6.
10
Influence of prior exposure to zidovudine on stavudine phosphorylation in vivo and ex vivo.
Antimicrob Agents Chemother. 2001 Feb;45(2):577-82. doi: 10.1128/AAC.45.2.577-582.2001.
引用本文的文献
1
Direct and indirect quantification of phosphate metabolites of nucleoside analogs in biological samples.
J Pharm Biomed Anal. 2020 Jan 30;178:112902. doi: 10.1016/j.jpba.2019.112902. Epub 2019 Oct 3.
2
Simultaneous quantification of intracellular lamivudine and abacavir triphosphate metabolites by LC-MS/MS.
J Pharm Biomed Anal. 2018 May 10;153:248-259. doi: 10.1016/j.jpba.2018.02.036. Epub 2018 Feb 20.
3
Intracellular pharmacokinetics of once versus twice daily zidovudine and lamivudine in adolescents.
Antimicrob Agents Chemother. 2007 Oct;51(10):3516-22. doi: 10.1128/AAC.01626-06. Epub 2007 Jul 30.
4
Determination of ddATP levels in human immunodeficiency virus-infected patients treated with dideoxyinosine.
Antimicrob Agents Chemother. 2004 Feb;48(2):589-95. doi: 10.1128/AAC.48.2.589-595.2004.
5
Simultaneous quantitation of the 5'-triphosphate metabolites of zidovudine, lamivudine, and stavudine in peripheral mononuclear blood cells of HIV infected patients by high-performance liquid chromatography tandem mass spectrometry.
J Am Soc Mass Spectrom. 2000 Dec;11(12):1134-43. doi: 10.1016/S1044-0305(00)00178-1.
6
Simultaneous quantitation of intracellular zidovudine and lamivudine triphosphates in human immunodeficiency virus-infected individuals.
Antimicrob Agents Chemother. 2000 Nov;44(11):3097-100. doi: 10.1128/AAC.44.11.3097-3100.2000.
7
Determination of zidovudine triphosphate intracellular concentrations in peripheral blood mononuclear cells from human immunodeficiency virus-infected individuals by tandem mass spectrometry.
Antimicrob Agents Chemother. 1999 Dec;43(12):2964-8. doi: 10.1128/AAC.43.12.2964.
8
High-performance liquid chromatographic determination of ribavirin in whole blood to assess disposition in erythrocytes.
Antimicrob Agents Chemother. 1999 Nov;43(11):2716-9. doi: 10.1128/AAC.43.11.2716.
9
Quantitation of intracellular triphosphate of emtricitabine in peripheral blood mononuclear cells from human immunodeficiency virus-infected patients.
Antimicrob Agents Chemother. 1999 Sep;43(9):2245-50. doi: 10.1128/AAC.43.9.2245.
10
Intracellular nucleotides of (-)-2',3'-deoxy-3'-thiacytidine in peripheral blood mononuclear cells of a patient infected with human immunodeficiency virus.
Antimicrob Agents Chemother. 1998 Nov;42(11):2989-95. doi: 10.1128/AAC.42.11.2989.
本文引用的文献
1
Phase I/II study of 3TC (lamivudine) in HIV-positive, asymptomatic or mild AIDS-related complex patients: sustained reduction in viral markers. The Lamivudine European HIV Working Group.
AIDS. 1995 Dec;9(12):1323-9. doi: 10.1097/00002030-199512000-00004.
2
Phase I evaluation of zidovudine administered to infants exposed at birth to the human immunodeficiency virus.
J Pediatr. 1993 Jan;122(1):137-44. doi: 10.1016/s0022-3476(05)83507-3.
3
Alternating and intermittent regimens of zidovudine and dideoxycytidine in patients with AIDS or AIDS-related complex.
Ann Intern Med. 1993 Mar 1;118(5):321-30. doi: 10.7326/0003-4819-118-5-199303010-00001.
4
Zidovudine response relationships in early human immunodeficiency virus infection.
Clin Pharmacol Ther. 1993 Nov;54(5):556-66. doi: 10.1038/clpt.1993.188.
5
Comparison of metabolism and in vitro antiviral activity of stavudine versus other 2',3'-dideoxynucleoside analogues.
J Infect Dis. 1995 Mar;171 Suppl 2:S88-92. doi: 10.1093/infdis/171.supplement_2.s88.
6
Clinical aspects of human immunodeficiency virus disease: clinical rationale for treatment.
J Infect Dis. 1995 Mar;171 Suppl 2:S81-7. doi: 10.1093/infdis/171.supplement_2.s81.
7
Evaluation of safety and efficacy of 3TC (lamivudine) in patients with asymptomatic or mildly symptomatic human immunodeficiency virus infection: a phase I/II study.
J Infect Dis. 1995 May;171(5):1166-71. doi: 10.1093/infdis/171.5.1166.
8
Cytotoxicity of 3'-azido-3'-deoxythymidine correlates with 3'-azidothymidine-5'-monophosphate (AZTMP) levels, whereas anti-human immunodeficiency virus (HIV) activity correlates with 3'-azidothymidine-5'-triphosphate (AZTTP) levels in cultured CEM T-lymphoblastoid cells.
Biochem Pharmacol. 1995 Mar 15;49(6):829-37. doi: 10.1016/0006-2952(94)00453-s.
9
A phase I/II evaluation of stavudine (d4T) in children with human immunodeficiency virus infection.
Pediatrics. 1995 Aug;96(2 Pt 1):247-52.
10
Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy.
Science. 1995 Aug 4;269(5224):696-9. doi: 10.1126/science.7542804.
Zotero 插件